/DNTH
DNTH Stock - Dianthus Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$42.44+1.65%
+$0.69 (+1.65%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.99
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+39.0%upside
Target: $58.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DNTH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$42.02 – $42.86
TARGET (TP)$59.00
STOP LOSS$39.04
RISK/REWARD1:4.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.19
52W High$45.46
52W Low$13.37
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.24M | $2.83M | $6.42M | $1.48M | N/A |
| Gross Profit | $6.24M | $2.83M | $6.42M | $1.48M | $-1,978,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-101,864,000 | $-48,174,000 | $-29,705,000 | $-13,086,000 | $-78,702,000 |
| Net Income | $-84,969,000 | $-43,555,000 | $-28,476,000 | $-13,109,000 | $-74,936,000 |
| Net Margin | -1362.8% | -1541.2% | -443.8% | -888.1% | N/A |
| EPS | $-2.55 | $-8.45 | $-7.60 | $-3.82 | $-27.30 |
Company Overview
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish0 Neutral/Bearish
Price Targets
$40
Average Target
↓ 5.7% Downside
Now
$22
Low
$40
Average
$58
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 14th 2025 | Truist | Initiation | Buy | $56 |
| July 2nd 2025 | William Blair | Initiation | Outperform | - |
| December 20th 2024 | TD Cowen | Initiation | Buy | - |
| October 3rd 2024 | Oppenheimer | Initiation | Outperform | $48 |
| July 26th 2024 | Robert W. Baird | Initiation | Outperform | $58 |
| June 27th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| May 16th 2024 | H.C. Wainwright | Initiation | Buy | $40 |
| February 15th 2024 | Stifel | Initiation | Buy | $44 |
| December 26th 2023 | Jefferies | Initiation | Buy | $22 |
| November 22nd 2023 | Wedbush | Initiation | Outperform | $23 |
| October 30th 2023 | Guggenheim | Initiation | Buy | $45 |
| September 28th 2023 | Raymond James | Initiation | Outperform | $24 |
Earnings History & Surprises
DNTHBeat Rate
47%
Last 15 quarters
Avg Surprise
-34.0%
EPS vs Estimate
Beats / Misses
7/8
Last 12 quarters
Latest EPS
$-0.97
Q4 2025
EPS Surprise History
Q1 24
+36.0%
$-0.71vs$-1.11
Q2 24
-25.6%
$-0.54vs$-0.43
Q3 24
-2.0%
$-0.51vs$-0.50
Q4 24
-25.4%
$-0.74vs$-0.59
Q1 25
+4.7%
$-0.81vs$-0.85
Q2 25
+4.7%
$-0.82vs$-0.86
Q3 25
-2.3%
$-0.88vs$-0.86
Q4 25
-12.8%
$-0.97vs$-0.86
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-0.97 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.86 | $-0.97 | -12.8% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.86 | $-0.88 | -2.3% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.86 | $-0.82 | +4.7% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-0.85 | $-0.81 | +4.7% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.59 | $-0.74 | -25.4% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.50 | $-0.51 | -2.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.43 | $-0.54 | -25.6% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-1.11 | $-0.71 | +36.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.51 | $-3.78 | -641.2% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.19 | $-0.05 | +73.7% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-6.40 | $-7.70 | -20.2% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-4.10 | $-2.67 | +34.9% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | $-4.64 | $-2.10 | +54.7% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-5.44 | $-4.70 | +13.6% | ✓ BEAT |
Q2 2022 | May 16, 2022 | — | $-6.24 | — | — |
Q1 2022 | Mar 8, 2022 | $-5.09 | $-5.25 | -3.2% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | — | $-4.76 | — | — |
Q3 2021 | Aug 5, 2021 | — | $-5.04 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $47
📈 PositiveBenzinga•Nov 10, 2025, 12:35 PM
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $46
📈 PositiveBenzinga•Nov 6, 2025, 01:32 PM
Dianthus Therapeutics Q3 EPS $(0.97) Misses $(0.89) Estimate, Sales $396.000K Miss $576.400K Estimate
📉 NegativeBenzinga•Nov 5, 2025, 10:06 PM
Dianthus Therapeutics Reviews New Data From Phase 2 MaGic Trial Of Claseprubart In Generalized Myasthenia Gravis Presented At AANEM Annual Meeting
➖ NeutralBenzinga•Oct 29, 2025, 07:32 PM
Dianthus Therapeutics Signs Exclusive License Deal With Leads Biolabs For DNTH212, A Phase 1 Ready Bifunctional Autoimmune Drug
📈 PositiveBenzinga•Oct 16, 2025, 11:07 AM
Truist Securities Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $56
📈 PositiveBenzinga•Oct 14, 2025, 01:07 PM
Clear Street Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $100
📈 PositiveBenzinga•Sep 17, 2025, 01:45 PM
Stifel Maintains Buy on Dianthus Therapeutics, Raises Price Target to $65
📈 PositiveBenzinga•Sep 12, 2025, 02:32 PM•Also:
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $44
📈 PositiveBenzinga•Sep 12, 2025, 12:10 PM
Reported Earlier, Dianthus Therapeutics Prices $251M Public Offering Of 6,487,879 Common Shares At $33 Per Share And 1,112,121 Pre-Funded Warrants
➖ NeutralBenzinga•Sep 10, 2025, 06:59 AM
Dianthus Therapeutics shares are trading higher after Raymond James reiterates Outperform rating on the stock and raises price target to $63. Guggenheim also maintains a Buy rating and raises its price target to $100.
📈 PositiveBenzinga•Sep 9, 2025, 05:43 PM
Raymond James Reiterates Outperform on Dianthus Therapeutics, Raises Price Target to $63
📈 PositiveBenzinga•Sep 9, 2025, 03:09 PM
Guggenheim Maintains Buy on Dianthus Therapeutics, Raises Price Target to $100
📈 PositiveBenzinga•Sep 9, 2025, 01:02 PM
Baird Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $67
📈 PositiveBenzinga•Sep 9, 2025, 11:40 AM
Dianthus Therapeutics Announces Proposed $150M Underwritten Public Offering Of Its Shares Of Common Stock
➖ NeutralBenzinga•Sep 8, 2025, 08:01 PM
DNTH stock has given up its prior loss. Dianthus Therapeutics shares were trading lower.
📈 PositiveBenzinga•Sep 8, 2025, 02:20 PM
Dianthus Therapeutics shares are trading lower. The company announced top-line data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive generalized Myasthenia Gravis.
📉 NegativeBenzinga•Sep 8, 2025, 12:44 PM
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 12:16 PM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 8, 2025, 11:25 AM
Dianthus Therapeutics Announces Claseprubart Phase 2 Results Supporting Single Convenient Self-Administered Subcutaneous Autoinjector Dosage Every Two Weeks For gMG
📈 PositiveBenzinga•Sep 8, 2025, 11:08 AM
Frequently Asked Questions about DNTH
What is DNTH's current stock price?
Dianthus Therapeutics, Inc. (DNTH) is currently trading at $42.44 per share. The stock has moved +1.65% today.
What is the analyst price target for DNTH?
The average analyst price target for DNTH is $59.00, based on 1 analyst.
What sector is Dianthus Therapeutics, Inc. in?
Dianthus Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DNTH's market cap?
Dianthus Therapeutics, Inc. has a market capitalization of $1.54 billion, making it a small-cap company.
Does DNTH pay dividends?
No, Dianthus Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
ATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
TSHA
Taysha Gene Therapies, Inc.
$5.49
Mkt Cap: $1.6B
Explore stocks similar to DNTH for comparison